Eos SENOLYTIX Announced Keynote for Mitochondria Congress
The Houston-based biotech firm prepares for a major industry presentation ahead of its upcoming merger vote.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical mergers typically lead to better treatment options for patients?
Eos SENOLYTIX has confirmed a keynote address at the 17th World Congress on Targeting Mitochondria to highlight its proprietary geropeptide candidate, PTC-2105. This presentation occurs as the company moves toward finalizing its merger with Pulmatrix.
Why it matters
The company aims to advance its pipeline focused on metabolic health and physical function, with the merger expected to provide the capital necessary for reaching clinical milestones. The upcoming stockholder vote is a pivotal step in establishing the combined entity.
Eos SENOLYTIX is currently developing PTC-2105, a proprietary MitoXcel geropeptide candidate. The broader field of healthspan research, in which the team recently won an XPRIZE award, is supported by a total competition funding pool of $101 million.
The players
Eos SENOLYTIX
This Houston-based biotechnology company focuses on developing therapeutics that improve metabolic health and physical function.
Pulmatrix
This clinical-stage biopharmaceutical company specializes in developing inhaled therapies for respiratory diseases and is currently merging with Eos.
Kevin Slawin
He is a leading executive at Eos SENOLYTIX who will provide the industry keynote address at the upcoming scientific congress.
The details
Kevin Slawin will deliver the keynote address in Berlin, detailing Eos research into therapeutics designed to improve body composition and metabolic health. Meanwhile, Pulmatrix has filed a Form S-4 registration statement with the SEC as the firm prepares for a special stockholder meeting.
Timeline
March 26, 2026: Eos and Pulmatrix entered into a merger agreement.
September 17, 2026: The Form S-4 registration statement for the merger was amended.
October 16, 2026: Pulmatrix stockholders will hold a special meeting to vote on the merger.
October 21-23, 2026: Eos will present at the 17th World Congress on Targeting Mitochondria in Berlin.
The Big Picture
The Eos and Pulmatrix merger follows the trend set by the XPRIZE Healthspan competition. The partnership aims to accelerate the development of geropeptide therapeutics within the competitive landscape of metabolic science.
For current stakeholders, the upcoming vote on October 16 will determine the path forward for the combined company, which intends to list on Nasdaq under the ticker symbol MTXL. The progress of the pipeline remains the primary indicator of long-term value for investors.
The takeaway
The convergence of Eos SENOLYTIX and Pulmatrix signals a strategic consolidation in the biotech sector aimed at fast-tracking experimental geropeptide treatments. Investors and industry observers should watch for the Q4 2026 merger closure as a milestone for the combined firm's commercial debut.
What happens next
Pulmatrix stockholders are scheduled to hold a special meeting to vote on the merger agreement on October 16, 2026.
Further reading
For more information on current industry developments, visit the Biotech section.
More information
View the current Pulmatrix inhaled product candidates pipeline on the company's official site.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical mergers typically lead to better treatment options for patients?
